Kornimate/medical-research-clean huggingface dataset:
astigmatic vector analysis of posterior cornea - a comparison among healthy, forme fruste and overt keratoconus corneas

Conditions: Keratoconus

Summary: the main purpose of this study is to determine new diagnostic criteria for an eye disease called keratoconus.

eyes of patients who distinctly present signs of keratoconus, for both eyes, at corneal tomography (an exam commonly used in such cases), and those who present such signs in only one eye were compared to eyes of unaffected patients. several characteristics of anterior and posterior corneal astigmatism (special emphasis was given to the latter) were collectively assessed among all patients by a method referred to as vectorial analysis. statistical tests were then performed, in an attempt to highlight differences among those three groups of patients and, eventually, define new diagnostic criteria.

Eligibility criteria:
inclusion criteria: * good-quality scheimpflug scans (approved by the device in the ''examination quality specification''). exclusion criteria: * previous eye surgery or trauma, and any sort of corneal scarring that might interfere with keratometric data acquisition.

Keywords: keratoconus corneal topography diagnosis keratomileusis, laser in situ
endoscopic submucosal dissection registry

Conditions: Gastrointestinal Neoplasms; Gastric Cancer

Summary: the purpose of this study is to monitor the success rates and completion rates for endoscopic submucosal dissection (esd) for gastrointestinal (gi) cancers.


Eligibility criteria:
inclusion criteria: patients referred for endoscopic treatment of advanced gastrointestinal (colorectal, gastric, duodenal, esophagus) neoplasia, defined by any of the following procedures: 1. flat dysplastic lesion greater than 2cm(iia or iib by paris classification) 2. flat depressed lesion \< 2cm in size (llc by paris classification) 3. ulcerated lesion \< 2cm (paris type lll) staged as t1n0 on endoscopic ultrasound 4. upon resection, the criteria for curative esd include: * non-invasive neoplasia of differentiated carcinoma * no lymphovascular invasion * intramucosal cancer or minute submucosal cancer \<1 mm invasion (sm1) * negative deep and lateral margins. exclusion criteria: 1. use of antiplatelet(e.g. clopidrogel) or anticoagulation (e.g. coumadin) agents that cannot be withheld for at least 7 days prior to the procedure. aspirin use is accepted according to the american society for gastrointestinal endoscopy for these procedures. 2. patients who refuse or who are unable to consent. 3. suboptimal colon prep, or solid gastric residual that precludes safe lesion resection at the time of endoscopy. 4. lesion location in a segment of the colon not conducive to esd, including significant narrowing, tortuosity and/or extensive diverticular disease, as determined by the endoscopist.

Keywords: gastrointestinal neoplasia submucosal resection
evaluation of the viability and safety of early discharge protocol after tavi implantation

Conditions: Aortic Valve Disease; Aortic Valve Stenosis; Heart Valve Diseases

Summary: evaluation of the safety and efficacy of early discharge (24 hours) after transfemoral transcatheter aortic prosthesis implantation (tavi).

evaluation of the safety and efficacy of early discharge (24 hours) after transfemoral transcatheter aortic prosthesis implantation (tavi).

Eligibility criteria:
inclusion criteria: patients who meet all of the following conditions will be included: * patients ≥ 18 years undergoing transfemoral tavi implantation scheduled, performed on an outpatient basis. * patients with percutaneous implant. * patients undergoing the procedure under superficial sedation or local anesthesia. * patients with baseline narrow qrs that does not change after implantation, or definitive pacemaker carrier. * patients who have signed the informed consent. exclusion criteria: patients who do not meet any of the following conditions: * patients with a wide qrs (greater than or equal to 120 msec) at baseline, with the except for patients with permanent pacemakers. * hospitalized patients undergoing urgent tavi implantation. * patients with access other than percutaneous transfemoral.
impact of antiviral therapy on gastroesophageal varices.

Conditions: Chronic Hepatitis C; Cirrhosis

Summary: hepatitis c virus (hcv) chronic infection affects 200 million people worldwide. hcv antiviral treatment has evolved rapidly since 2011. the use of pegylated interferon (peg-inf) with ribavirin (rbv) has supposed high serious adverse events (saes) and low efficacy, especially in patients with cirrhosis. the introduction of 1st generation protease inhibitors (pis) in genotype-1 (gt1) hcv, such as boceprevir (boc) and telaprevir (tvr), improved the efficacy but increased the saes. currently, interferon-free direct-acting antivirals (if-daas) achieve great effectiveness with minimum saes. however, studies evaluating efficacy and safety of daas in cirrhotic patients are limited in real clinical practice. the aim of our study is to evaluate in hcv-cirrhotic patients the efficacy and safety of 3 treatment strategies (peg-ifn/rbv, peg-ifn/rbv/pis, and if-daas) in routine practice according to european guidelines from 2010 to 2015. the secondary aim is to evaluate the impact of sustained virological response on gastroesophageal varices (gov).


Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * signed informed consent. * chronic hepatitis c (anti-hcv antibodies and detectable hcv-rna). * liver cirrhosis (transient elastography ≥ 14 kpa). * baseline upper gastrointestinal endoscopy to assess gastroesophageal varices exclusion criteria: * negative to provide signed informed consent. * negative to perform gastrointestinal endoscopy
a prospective, randomized trial of the effect of standard of care reduced dose versus full dose buprenorphine/naloxone in the perioperative period on pain control and post-operative opioid use disorder symptoms

Conditions: Opioid-use Disorder; Opioid Use Disorder, Mild

Summary: the purpose of this research study is to compare two ways of managing pain in people who are taking buprenorphine and are scheduled to undergo surgery. buprenorphine (subutex) and buprenorphine/naloxone (suboxone) are effective long-term treatments for substance use disorders. the management of pain after surgery in adults taking buprenorphine can be challenging, as buprenorphine may interfere with the effectiveness of other medications used to treat pain. we want to compare how well pain is managed after surgery ("post-op") in two groups: the "continue group": those who continue taking their standard dose of buprenorphine before, during and after surgery. the "reduce group": those who are placed on a lower dose of buprenorphine starting one day before surgery and during the time period after surgery until the pain from the surgery has decreased. once the pain from the surgery has decreased, you will be put back on your full dose of buprenorphine. we also want to find out if there is a difference in pain, opioid cravings, and relapse rates in the month following surgery.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) health class i-iii * currently taking buprenorphine or buprenorphine/naloxone daily at a dose of at least 16mg per day for at least the prior 30 days for treatment of opioid use disorder by diagnostic and statistical manual of mental disorders (dsm-v) criteria * scheduled for surgery at massachusetts general hospital where greater than 3/10 pain is expected on post-operative day 1 exclusion criteria: * participants unable to consent to the study * renal insufficency with a glomerular filtration rate \<30ml/min (participants would be unable to use ketorolac which is a part of the multimodal anesthetic plan) * liver cirrhosis with a model for end-stage liver disease (meld) score \> 25 (participants would be unable to use tylenol which is part of the multimodal anesthetic plan)
c-brace versus sco in community ambulators

Conditions: Lower Limb; Pareses

Summary: the purpose of this multicentric study is to assess the impact of c-brace on mobility, endurance, confidence, participation, satisfaction, psychosocial adjustment and quality of life in community ambulators using a stance control orthosis.

during two months of inclusion period, the investigators invite all patients matching with inclusion criteria for an enrolment visit, collect written consent and record general patient information. the ecrf (electronic case report form) assigns the enrolled patient into one group for the trial (c-brace/sco or sco/c-brace), in a randomized order. the assessments are performed after 2 month follow-up period with each orthosis with a minimal wash-out period of 2 weeks.

Eligibility criteria:
inclusion criteria: * person with knee locking deficiency * person using a sco (stance control orthosis) for at least three months, walking with a swing phase on a flat ground, without walking aid or with one cane or one crutch. * person having the ability to walk at 3km/h (measured with 10 meters walk test) with the sco in unlocked mode. * person with a stable stance phase on the contralateral side exclusion criteria: * person with deficient or unstable contralateral knee, including person using a knee-ankle foot orthosis on the contralateral limb * person walking using two canes, two crutches, one or two underarm crutches or a walker * person with health condition not compatible with the study protocol * person under 18 years old * person unwilling / unable to follow the entire study protocol / instructions * person who did not give her written consent to participate to the study or unable to personally give her consent * person with knee and/or hip flexion contracture \>10° * person with genu varum / valgum \> 10° (not reducible) * person with moderate to severe spasticity * person with leg length discrepancy \> 15cm * person who necessitate the use of an orthoprosthesis * person with body weight \> 125kg * person with unstable trunk in standing position * person with cognitive impairments

Keywords: knee-ankle-foot orthosis kafo
opioid-free accelerated recovery total knee arthroplasty

Conditions: Arthropathy of Knee Joint

Summary: to prove that total knee arthroplasty can be performed with little, if any need for opioids by using a combination of patient education, optimized pre-op and post-op pain and recovery protocols. the goal being opioid-free total knee arthroplasty.

all study patients will receive a standardized protocol * all surgical procedures performed by single surgeon using same implants, approach, pre-op and post-op optimization, and simplified pain protocol at a single hospital or surgery center * will attempt to minimize the number of anesthesiologists to further control variability in care methods: 1. pre-op optimization * all patients enroll in education program * all patients have optimized bmi, hemoglobin, albumin, glucose control-a1c, and blood pressure 2. total joint procedure * tourniquet-free cemented total knee arthroplasty is performed with intra-articular block 3. data collection * electronic medical record chart review * pre-op assessment and post-op assessment (post anesthesia care unit (pacu), phase ii-prior to discharge * phone calls after discharge * follow-up assessment in surgeon's office * swift path / koos jr surveys 4. pain management regimen * pre-op physical therapy teaching * post-op multimodal pain regimen

Eligibility criteria:
inclusion criteria: * surgeries to be performed at hospital * surgeries to be performed at surgery center * ability to read and understand english * primary care clearance for patients diagnosed with high blood pressure exclusion criteria: * disease states, patient conditions to exclude: schizophrenia bipolar disease dementia * known allergies to local anesthetics * previous burn to affected extremity * bmi \> 40 * nonoptimized anemia * albumin less than 3.5 * a1c \> 8.0
a study of cm310 in subjects with moderate to severe asthma

Conditions: Asthma

Summary: this study is a multi-center, randomized, double-blind, placebo-controlled phase ii clinical study to evaluate the efficacy, safety, pk characteristics, pd effects and immunogenicity of cm310 in subjects with moderate to severe asthma. the study consists of three periods, including an up to 4-week screening period, a 24-week randomized treatment period, and a 8-week safety follow-up period.


Eligibility criteria:
inclusion criteria: * subjects are able to understand the nature of the study and voluntarily sign the icf. * diagnosed with asthma according to the 2021 version of the gina guidelines for at least 1 year. * pre-bronchodilator fev1 measurement ≤ 80% of predicted normal value. * subjects must have experienced a severe asthma exacerbation within 12 months prior to screening, and have not experienced a severe asthma exacerbation within 1 month prior to screening. exclusion criteria: * women of childbearing potential have a positive pregnancy test result during the screening period; women who are pregnant or lactating. * received biologics with the same therapeutic purpose within 6 months prior to screening, such as similar il-4rα antagonist, il-5/5r, anti-ige monoclonal antibody (mab). * diagnosed with chronic obstructive pulmonary disease (copd) or other lung disorders that may compromise lung function (including but not limited to idiopathic pulmonary fibrosis, allergic granulomatous angiitis, bronchopulmonary aspergillosis allergic, pulmonary tuberculosis, etc.).
an examination of predictors of indicators of response to letrozole 2.5 mg

Conditions: Breast Cancer

Summary: to assess the quantitative real time pcr results of oligonucleotide probes for a number of gene transcription products that may be useful as predictors or indicators of response to letrozole

to assess the quantitative real time pcr results of oligonucleotide probes for a number of gene transcription products (pcna, cyclin-d1, er alpha, pr, ps2, 450 aromatase, bcl-2, bax, caspase-3, and vegfr) that may be useful as predictors or indicators of response to letrozole

Eligibility criteria:
inclusion criteria: * evidence of hyperplasia with/without atypia upon random periareolar fine needle aspiration of breast * on hormone replacement therapy * postmenopausal * increased risk of developing breast cancer based on personal or family history * never have taken aromatase inhibitors or selective estrogen receptor modulators in last six months * women who have a high risk of breast cancer * older than 18 years exclusion criteria: * no anticoagulants * no marked breast tenderness * not pregnant or within twelve months of breast feeding/childbirth

Keywords: breast atypia breast epithelial hyperplasia ki-67 rtpcr microdissection
efficacy of intravenous dexamethasone for acute disc herniation-induced sciatica

Conditions: RADICULAR PAIN

Summary: acute low back pain is one of the most common reasons for all physician visits(1). phospholipase a2 (pla2), a potent inflammatory mediator, has demonstrated to be released by discs following injury(4). clinical practice and animal research suggest that lumbar radicular pain is the result of inflammation of the nerve root in the epidural space(5). the study will evaluate the efficacy of intravenous dexamethasone for acute disc herniation-induced sciatica. 40 patients aged 18 years or older, who will be transferred to the emergency room due to sciatic pain will be blindly randomized to receive dexamethasone 30 mg iv for 3 days an tapering off, 10 mg daily, or normal saline. 20 patients will be in each group. the patients will continue their standard care during the study period. follow up will last for 3 months. mann-whitney test will be used for parametric correlation, wilcoxon for numeral and x² for categorial variables. dexamethasone iv can help physicians in treating patients with acute sciatic pain.


Eligibility criteria:
inclusion criteria: * patients aged 18 years or older presented with acute radicular pain for less than 6 weeks. exclusion criteria: * patient with acute infection, * psychiatric disorder, * uncontroled diabetes, * uncontrolede hypertension, * severe congestive heart failure, * cauda equina syndrome, * moderate or severe motor deficit, * primary spinal stenosis, * pregnancy.

Keywords: radicular pain disc herniation dexamethasone vas
clinical investigation of the efficacy of cgf and ozone in the treatment of alveolar osteitis

Conditions: Alveolar Osteitis

Summary: the aim of this study is to investigate the efficacy of cgf and ozone in the treatment of alveolitis and to develop a new treatment protocol that can enable a quick and effective solution of this clinical problem, which significantly affects patients' comfort of life.

in the present study, 60 healthy patients \> 18 years old and have alveolitis, will included. 60 patient will divided randomly into three groups as control, ozone and ozone+cgf. after irrigation of the sockets alvogyl, ozone and ozone+cgf will applied to the sockets respectively. post operative pain, will measured at 1st to 7th days. post operative infection, and granulation tissue will measured at 1st, 3rd and 7th days. oral hygiene will evaluated at first visit. quality of life will evaluated at 7th day.

Eligibility criteria:
inclusion criteria: patients who have one or more of the following in addition to severe pain, which occur within and around the socket 1-3 days after extraction and do not decrease with pain killers; * with a partially or completely disintegrated blood clot in the socket * with exposed bone that gives a dark gray appearance * with bad odor exclusion criteria: * who does not want to be volunteer for the study, * smokers, * during pregnancy or lactation, * has a chronic systemic disorder that will affect recovery, * has hematological disorder * cooperation cannot be established, * previously received radiotherapy or chemotherapy, * patients using oral contraceptives

Keywords: alveolitis dry socket ozone cgf
validation of the french version of the hearing aid benefit measurement cosi and ioi-ha questionnaires

Conditions: Hearing Impairment

Summary: estimating patient satisfaction is essential in modern day-to-day medical practice. this is particularly true in the field of audiology where evaluating the benefit of patients' devices makes it possible to improve settings and increase patient satisfaction and therefore compliance. questionnaires measuring hearing aid benefit such as the ioi-ha (international outcome inventory for hearing aids) and the cosi (client oriented scale of improvement) are used in everyday practice and promote cooperation between researchers by providing comparable data. unlike other countries, these questionnaires have never been validated in french by psychometric studies. the objective of this study is to validate the translation of the ioi-ha questionnaire already used in the clinic and to adapt the cosi into french and statistically validate its translation.

recruitment of cases via the otological consultation of the ent department, among patients consulting for hearing aids. inclusion will be suspended once 100 tests and at least 35 re-tests have been completed. inclusion (d0): * audiometry (as part of treatment) * clinical evaluation (as part of treatment) * passing the french version of the cosi and ioi-ha questionnaires visit 1 (d0 +3±1 week): only for 35 patients second administration of the french version of the cosi and ioi-ha questionnaires either by telephone, or during a second consultation or hospitalization, if this occurs within a compatible time frame.

Eligibility criteria:
inclusion criteria: * patients \> 18 years old * diagnosis of deafness with unilateral or bilateral hearing aid * informed consent to participate in the study * good understanding of french * non-opposition to participation in the study exclusion criteria: * comorbidity that may hamper the interpretation of results (e.g. disabling cognitive disorder)
influence of triflusal on cognitive functions in subjects under chronic stress

Conditions: Healthy

Summary: the purpose of this study is to investigate the effects of the enos activating agent triflusal on episodic memory and cognitive functions in participants under chronic stress.

randomised, placebo controlled, double blind, cross-over design primary study outcome is: performance in a verbal memory task. main secondary outcomes are: performance in working memory and cognitive tasks and influence on mood, depression and anxiety and subjective memory impairment. once daily oral administration of 600 mg triflusal and placebo mannitol for 8 days in a cross-over trial with a washout period of at least 14 days between the two periods. each participant will take triflusal as well as placebo

Eligibility criteria:
inclusion criteria: * male or female * normotensive (bp between 90/60mmhg and 140/90mmhg) * bmi between 19 and 29 kg/m2 * aged between 18 and 40 years * experiencing chronic stress for at least 1 month (tics sum score in subscale "overextension at work" \>= 55) * native or fluent german-speaking * able and willing to give written informed consent as documented by signature and comply with the requirements of the study protocol * willing to donate saliva sample for dna-analysis * female: willing to perform a pregnancy test at the beginning of both medication phase and at the follow-up visit. exclusion criteria: * contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to salicylates and other nsaids * acute or chronic psychiatric disorder (e.g. major depression, psychoses, somatoform disorder, suicidal tendency) except symptoms of chronic stress * cognitive impairment as detected by demtect * concomitant acute or chronic disease state (e.g. renal failure, hepatic dysfunction, cardiovascular disease, acute infections etc.) * women who are pregnant or breast feeding * intention to become pregnant during the course of the study * lack of safe contraception, defined as: female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases * active peptic ulcer or antecedents or complicated peptic ulcer or history of peptic ulcer. any other active pathological bleeding * history of coagulation abnormality * thyroid problems * laboratory exclusion criteria: clinically significant values of blood count (incl. platelets), coagulation status or blood chemistry outside reference range of laboratory * pathological ecg * known or suspected non-compliance, drug or alcohol abuse * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant * participation in another study with investigational drug within the 30 days preceding -
emotional intelligence in patients with addictive disorder

Conditions: Substance Use Disorders

Summary: the study aims to evaluate the level of emotional intelligence in patients diagnosed with substance use disorder and to evaluate the benefits in emotional skills after a brief intervention based on emotional intelligence.

patients will be recruited by consecutive non-probabilistic sampling in the addictions day hospital of the addictions unit of the hospital de la santa creu i sant pau in barcelona. the level of emotional intelligence will be assessed through the following measurement instruments: msceit for the objective emotional intelligence coefficient and the tmms-24 for the perceived emotional intelligence. patients will attend 9 sessions of brief group intervention based on emotional intelligence and pre-post intervention differences in participants' tmms-24 scores will be analyzed

Eligibility criteria:
inclusion criteria: * substance use disorder (dsm-5) * 18 to 80 years old exclusion criteria: * presence of severe psychopathological alteration (including severe intoxication) * inability to understand the spanish language or difficulties writing or reading